Background:

Coumetarol (Dicumoxane) is a vitamin K antagonist.

Coumetarol (Dicumoxane), an oral anticoagulant, is active in both models. The vitamin K antagonist Coumetarol is effective in both models after oral treatment but inhibits the thrombus formation more strongly in the arterio-venous shunt model. Treatment with the vitamin K antagonist Coumetarol in a dose of 25 mg/kg p.o. twice daily for 2 days results in a significant reduction in thrombus weight by 50% in the venous stasis model and by 75% in the arterio-venous shunt model. In both experiments the coagulation time as measured by the Thrombotest is prolonged to the same extent[1].

[1]. Vogel GM, et al. Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans. Thromb Res. 1989 Jun 1;54(5):399-410.